Key result
Statin use, such as rosuvastatin, may be associated with reductions in the risk of venous thromboembolism, highlighting a potential novel pleiotropic effect.
Why the study?
Do statins reduce the risk of venous thromboembolism?
Do statins reduce the risk of venous thromboembolism?
This editorial highlights a potential pleiotropic effect of statins in reducing venous thromboembolism risk, based on findings from the JUPITER trial.
Statins play a key role in the management of hypercholesterolemia and other dyslipidemias. However, statins exert several other actions, often referred to as 'pleiotropic'. This Editorial looks at the JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), examining, in particular, the occurrence of venous thromboembolism in the rosuvastatin and placebo groups, and discussing these findings in the context of the current literature. The authors conclude that statin use could perhaps be associated with reductions in the risk of venous thromboembolism, and call for further appropriately designed studies.
No takes yet. Share an insight, caveat, or question.
Paraskevas et al. (2009) conducted an editorial in Hypercholesterolemia and other dyslipidemias. Statins (rosuvastatin) vs. Placebo was evaluated on Venous thromboembolism. Statin use, such as rosuvastatin, may be associated with reductions in the risk of venous thromboembolism, highlighting a potential novel pleiotropic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: